#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


1-1	0-3	The	_
1-2	4-16	relationship	_
1-3	17-24	between	_
1-4	25-38	interleukin-6	_
1-5	39-42	and	_
1-6	43-53	functional	_
1-7	54-66	connectivity	_
1-8	67-69	in	_
1-9	70-85	methamphetamine	http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence
1-10	86-91	users	http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence
1-11	92-107	Methamphetamine	http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence
1-12	108-109	(	http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence
1-13	110-112	MA	http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence
1-14	113-114	)	http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence
1-15	115-121	causes	_
1-16	122-124	an	_
1-17	125-133	increase	_
1-18	134-136	in	_
1-19	137-153	pro-inflammatory	_
1-20	154-163	cytokines	_
1-21	164-166	in	_
1-22	167-173	animal	_
1-23	174-180	models	_
1-24	181-184	and	_
1-25	185-187	in	_
1-26	188-194	humans	_
1-27	195-196	.	_

2-1	197-206	Resulting	_
2-2	207-217	activation	_
2-3	218-220	of	_
2-4	221-230	microglia	_
2-5	231-234	and	_
2-6	235-253	neuro-inflammation	_
2-7	254-259	could	_
2-8	260-261	,	_
2-9	262-265	via	_
2-10	266-273	effects	_
2-11	274-276	on	_
2-12	277-283	reward	_
2-13	284-292	networks	_
2-14	293-294	,	_
2-15	295-302	mediate	_
2-16	303-313	behavioral	_
2-17	314-329	characteristics	_
2-18	330-332	of	_
2-19	333-342	addiction	_
2-20	343-344	.	_

3-1	345-347	We	_
3-2	348-356	examined	_
3-3	357-360	the	_
3-4	361-373	relationship	_
3-5	374-381	between	_
3-6	382-395	interleukin-6	_
3-7	396-397	(	_
3-8	398-402	IL-6	_
3-9	403-404	)	_
3-10	405-408	and	_
3-11	409-422	corticolimbic	_
3-12	423-426	and	_
3-13	427-440	striatolimbic	_
3-14	441-454	resting-state	_
3-15	455-465	functional	_
3-16	466-478	connectivity	_
3-17	479-480	(	_
3-18	481-485	RSFC	_
3-19	486-487	)	_
3-20	488-489	.	_

4-1	490-496	Thirty	_
4-2	497-503	adults	_
4-3	504-513	diagnosed	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
4-4	514-518	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
4-5	519-521	MA	http://maven.renci.org/NeuroBridge/neurobridge#PolysubstanceDependence
4-6	522-532	dependence	http://maven.renci.org/NeuroBridge/neurobridge#PolysubstanceDependence
4-7	533-536	and	_
4-8	537-539	20	_
4-9	540-547	control	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
4-10	548-556	subjects	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
4-11	557-566	underwent	_
4-12	567-568	a	_
4-13	569-582	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
4-14	583-593	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
4-15	594-602	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
4-16	603-612	resonance	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
4-17	613-620	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
4-18	621-622	(	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
4-19	623-627	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
4-20	628-629	)	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
4-21	630-634	scan	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
4-22	635-638	and	_
4-23	639-643	gave	_
4-24	644-645	a	_
4-25	646-651	blood	_
4-26	652-658	sample	_
4-27	659-662	for	_
4-28	663-676	determination	_
4-29	677-679	of	_
4-30	680-686	plasma	_
4-31	687-691	IL-6	_
4-32	692-698	levels	_
4-33	699-700	.	_

5-1	701-711	Seed-based	_
5-2	712-716	RSFC	_
5-3	717-725	analyses	_
5-4	726-730	were	_
5-5	731-740	performed	_
5-6	741-743	to	_
5-7	744-751	examine	_
5-8	752-755	the	_
5-9	756-767	interactive	_
5-10	768-774	effect	_
5-11	775-777	of	_
5-12	778-783	group	_
5-13	784-787	and	_
5-14	788-792	IL-6	_
5-15	793-795	on	_
5-16	796-803	ventral	_
5-17	804-812	striatal	_
5-18	813-816	and	_
5-19	817-827	prefrontal	_
5-20	828-840	connectivity	_
5-21	841-842	.	_

6-1	843-849	Within	_
6-2	850-853	the	_
6-3	854-856	MA	_
6-4	857-862	group	_
6-5	863-864	,	_
6-6	865-869	IL-6	_
6-7	870-876	levels	_
6-8	877-881	were	_
6-9	882-892	positively	_
6-10	893-900	related	_
6-11	901-903	to	_
6-12	904-917	striatolimbic	_
6-13	918-922	RSFC	_
6-14	923-926	but	_
6-15	927-937	negatively	_
6-16	938-945	related	_
6-17	946-948	to	_
6-18	949-964	corticostriatal	_
6-19	965-969	RSFC	_
6-20	970-971	.	_

7-1	972-975	Our	_
7-2	976-984	findings	_
7-3	985-989	with	_
7-4	990-994	IL-6	_
7-5	995-1002	support	_
7-6	1003-1006	the	_
7-7	1007-1011	idea	_
7-8	1012-1016	that	_
7-9	1017-1029	inflammation	_
7-10	1030-1033	may	_
7-11	1034-1036	at	_
7-12	1037-1042	least	_
7-13	1043-1049	partly	_
7-14	1050-1057	mediate	_
7-15	1058-1061	the	_
7-16	1062-1066	link	_
7-17	1067-1072	among	_
7-18	1073-1075	MA	http://maven.renci.org/NeuroBridge/neurobridge#Thing
7-19	1076-1079	use	_
7-20	1080-1088	disorder	_
7-21	1089-1090	,	_
7-22	1091-1095	RSFC	http://maven.renci.org/NeuroBridge/neurobridge#Thing
7-23	1096-1097	,	_
7-24	1098-1101	and	_
7-25	1102-1110	behavior	_
7-26	1111-1112	,	_
7-27	1113-1121	possibly	_
7-28	1122-1125	via	_
7-29	1126-1133	effects	_
7-30	1134-1136	on	_
7-31	1137-1147	mesolimbic	_
7-32	1148-1151	and	_
7-33	1152-1164	mesocortical	_
7-34	1165-1177	dopaminergic	_
7-35	1178-1185	systems	_
7-36	1186-1187	.	_

8-1	1188-1189	2	_
8-2	1190-1191	.	_

9-1	1192-1201	Materials	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
9-2	1202-1205	and	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
9-3	1206-1213	methods	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
9-4	1214-1217	2.1	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
9-5	1218-1219	.	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod

10-1	1220-1232	Participants	_
10-2	1233-1239	Thirty	_
10-3	1240-1250	volunteers	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
10-4	1251-1260	diagnosed	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
10-5	1261-1265	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
10-6	1266-1268	MA	http://maven.renci.org/NeuroBridge/neurobridge#PolysubstanceDependence
10-7	1269-1279	dependence	http://maven.renci.org/NeuroBridge/neurobridge#PolysubstanceDependence
10-8	1280-1283	and	_
10-9	1284-1286	20	_
10-10	1287-1294	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
10-11	1295-1303	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
10-12	1304-1312	provided	_
10-13	1313-1320	written	_
10-14	1321-1329	informed	_
10-15	1330-1337	consent	_
10-16	1338-1339	,	_
10-17	1340-1342	as	_
10-18	1343-1351	approved	_
10-19	1352-1354	by	_
10-20	1355-1358	the	_
10-21	1359-1367	Veterans	_
10-22	1368-1375	Affairs	_
10-23	1376-1384	Portland	_
10-24	1385-1391	Health	_
10-25	1392-1396	Care	_
10-26	1397-1403	System	_
10-27	1404-1405	(	_
10-28	1406-1414	VAPORHCS	_
10-29	1415-1416	)	_
10-30	1417-1420	and	_
10-31	1421-1427	Oregon	_
10-32	1428-1434	Health	_
10-33	1435-1436	&	_
10-34	1437-1444	Science	_
10-35	1445-1455	University	_
10-36	1456-1469	Institutional	_
10-37	1470-1476	Review	_
10-38	1477-1483	Boards	_
10-39	1484-1485	(	_
10-40	1486-1490	IRBs	_
10-41	1491-1492	)	_
10-42	1493-1494	.	_

11-1	1495-1498	The	_
11-2	1499-1503	work	_
11-3	1504-1507	was	_
11-4	1508-1515	carried	_
11-5	1516-1519	out	_
11-6	1520-1522	in	_
11-7	1523-1533	accordance	_
11-8	1534-1538	with	_
11-9	1539-1542	The	_
11-10	1543-1547	Code	_
11-11	1548-1550	of	_
11-12	1551-1557	Ethics	_
11-13	1558-1560	of	_
11-14	1561-1564	the	_
11-15	1565-1570	World	_
11-16	1571-1578	Medical	_
11-17	1579-1590	Association	_
11-18	1591-1592	(	_
11-19	1593-1604	Declaration	_
11-20	1605-1607	of	_
11-21	1608-1616	Helsinki	_
11-22	1617-1618	)	_
11-23	1619-1620	.	_

12-1	1621-1633	Participants	_
12-2	1634-1636	in	_
12-3	1637-1640	the	_
12-4	1641-1643	MA	http://maven.renci.org/NeuroBridge/neurobridge#Thing
12-5	1644-1649	group	_
12-6	1650-1654	were	_
12-7	1655-1664	recruited	_
12-8	1665-1672	through	_
12-9	1673-1677	word	_
12-10	1678-1680	of	_
12-11	1681-1686	mouth	_
12-12	1687-1688	,	_
12-13	1689-1701	IRB-approved	_
12-14	1702-1716	advertisements	_
12-15	1717-1718	,	_
12-16	1719-1722	and	_
12-17	1723-1732	referrals	_
12-18	1733-1737	from	_
12-19	1738-1746	VAPORHCS	_
12-20	1747-1748	,	_
12-21	1749-1752	the	_
12-22	1753-1762	community	_
12-23	1763-1764	,	_
12-24	1765-1768	and	_
12-25	1769-1773	from	_
12-26	1774-1783	addiction	_
12-27	1784-1793	treatment	_
12-28	1794-1801	centers	_
12-29	1802-1803	.	_

13-1	1804-1811	Control	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
13-2	1812-1824	participants	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
13-3	1825-1829	were	_
13-4	1830-1839	recruited	_
13-5	1840-1842	by	_
13-6	1843-1856	advertisement	_
13-7	1857-1861	from	_
13-8	1862-1865	the	_
13-9	1866-1873	general	_
13-10	1874-1880	public	_
13-11	1881-1884	and	_
13-12	1885-1889	from	_
13-13	1890-1897	friends	_
13-14	1898-1901	and	_
13-15	1902-1910	families	_
13-16	1911-1913	of	_
13-17	1914-1919	those	_
13-18	1920-1923	who	_
13-19	1924-1932	attended	_
13-20	1933-1936	the	_
13-21	1937-1944	clinics	_
13-22	1945-1955	associated	_
13-23	1956-1960	with	_
13-24	1961-1964	the	_
13-25	1965-1970	study	_
13-26	1971-1972	.	_

14-1	1973-1982	Exclusion	_
14-2	1983-1991	criteria	_
14-3	1992-1995	for	_
14-4	1996-2000	both	_
14-5	2001-2007	groups	_
14-6	2008-2009	,	_
14-7	2010-2020	determined	_
14-8	2021-2023	by	_
14-9	2024-2031	medical	_
14-10	2032-2039	history	_
14-11	2040-2043	and	_
14-12	2044-2054	laboratory	_
14-13	2055-2060	blood	_
14-14	2061-2066	tests	_
14-15	2067-2071	were	_
14-16	2072-2073	:	_
14-17	2074-2082	systemic	_
14-18	2083-2084	,	_
14-19	2085-2097	neurological	_
14-20	2098-2099	,	_
14-21	2100-2114	cardiovascular	_
14-22	2115-2116	,	_
14-23	2117-2119	or	_
14-24	2120-2129	pulmonary	_
14-25	2130-2137	disease	_
14-26	2138-2139	,	_
14-27	2140-2144	head	_
14-28	2145-2151	trauma	_
14-29	2152-2156	with	_
14-30	2157-2161	loss	_
14-31	2162-2164	of	_
14-32	2165-2178	consciousness	_
14-33	2179-2180	,	_
14-34	2181-2189	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
14-35	2190-2199	resonance	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
14-36	2200-2207	imaging	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
14-37	2208-2209	(	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
14-38	2210-2213	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
14-39	2214-2215	)	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
14-40	2216-2233	contraindications	_
14-41	2234-2235	,	_
14-42	2236-2239	use	_
14-43	2240-2242	of	_
14-44	2243-2254	medications	_
14-45	2255-2260	known	_
14-46	2261-2263	to	_
14-47	2264-2268	have	_
14-48	2269-2281	dopaminergic	_
14-49	2282-2292	mechanisms	_
14-50	2293-2294	(	_
14-51	2295-2299	e.g.	_
14-52	2300-2301	,	_
14-53	2302-2316	antipsychotics	_
14-54	2317-2318	,	_
14-55	2319-2334	antidepressants	_
14-56	2335-2336	,	_
14-57	2337-2353	antiparkinsonian	_
14-58	2354-2360	agents	_
14-59	2361-2362	)	_
14-60	2363-2364	,	_
14-61	2365-2383	sedative-hypnotics	_
14-62	2384-2385	(	_
14-63	2386-2398	barbiturates	_
14-64	2399-2400	,	_
14-65	2401-2416	benzodiazepines	_
14-66	2417-2418	,	_
14-67	2419-2427	zolpidem	_
14-68	2428-2429	)	_
14-69	2430-2432	or	_
14-70	2433-2449	anticholinergics	_
14-71	2450-2451	.	_

15-1	2452-2456	Past	_
15-2	2457-2459	or	_
15-3	2460-2467	Current	_
15-4	2468-2472	Axis	_
15-5	2473-2474	I	_
15-6	2475-2484	diagnoses	_
15-7	2485-2486	,	_
15-8	2487-2492	other	_
15-9	2493-2497	than	_
15-10	2498-2508	depression	_
15-11	2509-2510	,	_
15-12	2511-2524	posttraumatic	_
15-13	2525-2531	stress	_
15-14	2532-2540	disorder	_
15-15	2541-2543	or	_
15-16	2544-2552	nicotine	_
15-17	2553-2563	dependence	_
15-18	2564-2567	for	_
15-19	2568-2574	either	_
15-20	2575-2580	group	_
15-21	2581-2582	,	_
15-22	2583-2591	assessed	_
15-23	2592-2596	with	_
15-24	2597-2600	the	_
15-25	2601-2604	the	_
15-26	2605-2623	Mini-International	_
15-27	2624-2640	Neuropsychiatric	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
15-28	2641-2650	Interview	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
15-29	2651-2652	(	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
15-30	2653-2660	M.I.N.I	_
15-31	2661-2662	.	_

16-1	2663-2664	)	_
16-2	2665-2666	,	_
16-3	2667-2670	and	_
16-4	2671-2678	alcohol	_
16-5	2679-2682	use	_
16-6	2683-2684	>	_
16-7	2685-2686	7	_
16-8	2687-2695	standard	_
16-9	2696-2702	drinks	_
16-10	2703-2706	per	_
16-11	2707-2711	week	_
16-12	2712-2715	for	_
16-13	2716-2721	women	_
16-14	2722-2725	and	_
16-15	2726-2727	>	_
16-16	2728-2730	14	_
16-17	2731-2737	drinks	_
16-18	2738-2741	per	_
16-19	2742-2746	week	_
16-20	2747-2750	for	_
16-21	2751-2754	men	_
16-22	2755-2759	were	_
16-23	2760-2772	exclusionary	_
16-24	2773-2774	.	_

17-1	2775-2778	For	_
17-2	2779-2788	inclusion	_
17-3	2789-2791	in	_
17-4	2792-2795	the	_
17-5	2796-2798	MA	_
17-6	2799-2804	group	_
17-7	2805-2806	,	_
17-8	2807-2819	participants	_
17-9	2820-2823	met	_
17-10	2824-2830	DSM-IV	_
17-11	2831-2839	criteria	_
17-12	2840-2843	for	_
17-13	2844-2846	MA	_
17-14	2847-2857	dependence	_
17-15	2858-2861	and	_
17-16	2862-2865	had	_
17-17	2866-2870	been	_
17-18	2871-2880	abstinent	_
17-19	2881-2885	from	_
17-20	2886-2888	MA	_
17-21	2889-2892	for	_
17-22	2893-2894	>	_
17-23	2895-2896	1	_
17-24	2897-2902	month	_
17-25	2903-2906	and	_
17-26	2907-2908	<	_
17-27	2909-2910	6	_
17-28	2911-2917	months	_
17-29	2918-2919	(	_
17-30	2920-2924	Note	_
17-31	2925-2926	:	_
17-32	2927-2935	Although	_
17-33	2936-2939	the	_
17-34	2940-2949	currently	_
17-35	2950-2958	accepted	_
17-36	2959-2970	terminology	_
17-37	2971-2973	is	_
17-38	2974-2989	methamphetamine	_
17-39	2990-2993	use	_
17-40	2994-3002	disorder	_
17-41	3003-3004	,	_
17-42	3005-3007	as	_
17-43	3008-3011	per	_
17-44	3012-3015	the	_
17-45	3016-3021	DSM-5	_
17-46	3022-3023	,	_
17-47	3024-3027	the	_
17-48	3028-3038	diagnostic	_
17-49	3039-3047	category	_
17-50	3048-3051	was	_
17-51	3052-3062	previously	_
17-52	3063-3069	termed	_
17-53	3070-3072	MA	_
17-54	3073-3083	dependence	_
17-55	3084-3085	,	_
17-56	3086-3089	and	_
17-57	3090-3094	this	_
17-58	3095-3099	term	_
17-59	3100-3102	is	_
17-60	3103-3107	used	_
17-61	3108-3112	when	_
17-62	3113-3122	referring	_
17-63	3123-3125	to	_
17-64	3126-3129	the	_
17-65	3130-3138	research	_
17-66	3139-3151	participants	_
17-67	3152-3161	described	_
17-68	3162-3164	in	_
17-69	3165-3169	this	_
17-70	3170-3175	paper	_
17-71	3176-3177	)	_
17-72	3178-3179	.	_

18-1	3180-3185	Urine	_
18-2	3186-3193	testing	_
18-3	3194-3196	on	_
18-4	3197-3200	day	_
18-5	3201-3203	of	_
18-6	3204-3207	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImagingInstrument
18-7	3208-3212	scan	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImagingInstrument
18-8	3213-3221	verified	_
18-9	3222-3232	abstinence	_
18-10	3233-3237	from	_
18-11	3238-3245	cocaine	_
18-12	3246-3247	,	_
18-13	3248-3263	methamphetamine	_
18-14	3264-3265	,	_
18-15	3266-3281	benzodiazepines	_
18-16	3282-3283	,	_
18-17	3284-3287	and	_
18-18	3288-3295	opiates	_
18-19	3296-3297	.	_

19-1	3298-3301	2.2	_
19-2	3302-3303	.	_

20-1	3304-3309	Blood	_
20-2	3310-3316	sample	_
20-3	3317-3327	collection	_
20-4	3328-3331	and	_
20-5	3332-3342	processing	_
20-6	3343-3348	Blood	_
20-7	3349-3352	was	_
20-8	3353-3358	drawn	_
20-9	3359-3363	from	_
20-10	3364-3375	non-fasting	_
20-11	3376-3388	participants	_
20-12	3389-3391	at	_
20-13	3392-3396	rest	_
20-14	3397-3399	by	_
20-15	3400-3408	one-time	_
20-16	3409-3421	venipuncture	_
20-17	3422-3423	.	_

21-1	3424-3431	Samples	_
21-2	3432-3436	were	_
21-3	3437-3446	collected	_
21-4	3447-3449	in	_
21-5	3450-3454	cell	_
21-6	3455-3466	preparation	_
21-7	3467-3472	tubes	_
21-8	3473-3474	(	_
21-9	3475-3477	BD	_
21-10	3478-3488	Vacutainer	_
21-11	3489-3496	Systems	_
21-12	3497-3498	,	_
21-13	3499-3507	Franklin	_
21-14	3508-3513	Lakes	_
21-15	3514-3515	,	_
21-16	3516-3518	NJ	_
21-17	3519-3520	,	_
21-18	3521-3524	USA	_
21-19	3525-3526	)	_
21-20	3527-3537	containing	_
21-21	3538-3539	1	_
21-22	3540-3542	mL	_
21-23	3543-3545	of	_
21-24	3546-3550	0.1M	_
21-25	3551-3557	sodium	_
21-26	3558-3565	citrate	_
21-27	3566-3574	solution	_
21-28	3575-3576	.	_

22-1	3577-3580	The	_
22-2	3581-3586	blood	_
22-3	3587-3590	was	_
22-4	3591-3595	then	_
22-5	3596-3607	centrifuged	_
22-6	3608-3610	at	_
22-7	3611-3615	1500	_
22-8	3616-3619	RCF	_
22-9	3620-3623	for	_
22-10	3624-3626	20	_
22-11	3627-3634	minutes	_
22-12	3635-3637	at	_
22-13	3638-3642	room	_
22-14	3643-3654	temperature	_
22-15	3655-3656	(	_
22-16	3657-3663	22–25°	_
22-17	3664-3665	C	_
22-18	3666-3667	)	_
22-19	3668-3669	.	_

23-1	3670-3676	Plasma	_
23-2	3677-3680	was	_
23-3	3681-3690	separated	_
23-4	3691-3692	,	_
23-5	3693-3702	collected	_
23-6	3703-3706	and	_
23-7	3707-3718	immediately	_
23-8	3719-3728	aliquoted	_
23-9	3729-3731	in	_
23-10	3732-3745	polypropylene	_
23-11	3746-3751	tubes	_
23-12	3752-3753	(	_
23-13	3754-3760	Phenix	_
23-14	3761-3769	Research	_
23-15	3770-3778	Products	_
23-16	3779-3780	,	_
23-17	3781-3788	Hayward	_
23-18	3789-3790	,	_
23-19	3791-3793	CA	_
23-20	3794-3795	,	_
23-21	3796-3799	USA	_
23-22	3800-3801	)	_
23-23	3802-3805	and	_
23-24	3806-3812	frozen	_
23-25	3813-3815	at	_
23-26	3816-3820	−80°	_
23-27	3821-3822	C	_
23-28	3823-3828	until	_
23-29	3829-3836	assayed	_
23-30	3837-3838	.	_

24-1	3839-3844	Every	_
24-2	3845-3851	effort	_
24-3	3852-3855	was	_
24-4	3856-3860	made	_
24-5	3861-3863	to	_
24-6	3864-3871	collect	_
24-7	3872-3879	samples	_
24-8	3880-3887	between	_
24-9	3888-3890	11	_
24-10	3891-3893	AM	_
24-11	3894-3897	and	_
24-12	3898-3899	1	_
24-13	3900-3902	PM	_
24-14	3903-3904	(	_
24-15	3905-3912	average	_
24-16	3913-3923	collection	_
24-17	3924-3928	time	_
24-18	3929-3932	was	_
24-19	3933-3938	11:36	_
24-20	3939-3941	AM	_
24-21	3942-3943	)	_
24-22	3944-3945	;	_
24-23	3946-3950	mean	_
24-24	3951-3956	blood	_
24-25	3957-3967	collection	_
24-26	3968-3973	times	_
24-27	3974-3976	by	_
24-28	3977-3982	study	_
24-29	3983-3988	group	_
24-30	3989-3993	were	_
24-31	3994-3996	as	_
24-32	3997-4004	follows	_
24-33	4005-4006	:	_
24-34	4007-4014	Control	_
24-35	4015-4020	group	_
24-36	4021-4022	=	_
24-37	4023-4028	11:28	_
24-38	4029-4031	AM	_
24-39	4032-4035	and	_
24-40	4036-4038	MA	_
24-41	4039-4044	group	_
24-42	4045-4046	=	_
24-43	4047-4052	12:05	_
24-44	4053-4055	PM	_
24-45	4056-4057	.	_

25-1	4058-4061	2.3	_
25-2	4062-4063	.	_

26-1	4064-4073	Multiplex	_
26-2	4074-4085	immunoassay	_
26-3	4086-4091	Human	_
26-4	4092-4098	plasma	_
26-5	4099-4106	samples	_
26-6	4107-4111	were	_
26-7	4112-4120	analyzed	_
26-8	4121-4123	in	_
26-9	4124-4133	duplicate	_
26-10	4134-4139	using	_
26-11	4140-4141	a	_
26-12	4142-4152	customized	_
26-13	4153-4154	,	_
26-14	4155-4171	high-sensitivity	_
26-15	4172-4181	multiplex	_
26-16	4182-4193	polystyrene	_
26-17	4194-4204	bead-based	_
26-18	4205-4216	immunoassay	_
26-19	4217-4218	[	_
26-20	4219-4226	Luminex	_
26-21	4227-4238	Performance	_
26-22	4239-4244	Assay	_
26-23	4245-4246	(	_
26-24	4247-4250	cat	_
26-25	4251-4252	.	_

27-1	4253-4255	no	_
27-2	4256-4257	.	_

28-1	4258-4267	FCST09-03	_
28-2	4268-4269	)	_
28-3	4270-4271	;	_
28-4	4272-4273	R	_
28-5	4274-4275	&	_
28-6	4276-4277	D	_
28-7	4278-4285	Systems	_
28-8	4286-4287	,	_
28-9	4288-4299	Minneapolis	_
28-10	4300-4301	,	_
28-11	4302-4304	MN	_
28-12	4305-4306	,	_
28-13	4307-4310	USA	_
28-14	4311-4312	]	_
28-15	4313-4315	to	_
28-16	4316-4323	measure	_
28-17	4324-4334	peripheral	_
28-18	4335-4341	immune	_
28-19	4342-4352	biomarkers	_
28-20	4353-4363	associated	_
28-21	4364-4368	with	_
28-22	4369-4381	inflammation	_
28-23	4382-4383	,	_
28-24	4384-4396	specifically	_
28-25	4397-4401	IL-6	_
28-26	4402-4405	and	_
28-27	4406-4411	IL-1β	_
28-28	4412-4413	,	_
28-29	4414-4417	and	_
28-30	4418-4421	the	_
28-31	4422-4439	anti-inflammatory	_
28-32	4440-4448	cytokine	_
28-33	4449-4450	,	_
28-34	4451-4456	IL-10	_
28-35	4457-4458	.	_

29-1	4459-4462	The	_
29-2	4463-4484	manufacturer-reported	_
29-3	4485-4490	lower	_
29-4	4491-4500	detection	_
29-5	4501-4507	limits	_
29-6	4508-4512	were	_
29-7	4513-4517	0.31	_
29-8	4518-4523	pg/ml	_
29-9	4524-4527	for	_
29-10	4528-4532	IL-6	_
29-11	4533-4534	,	_
29-12	4535-4539	0.18	_
29-13	4540-4545	pg/ml	_
29-14	4546-4549	for	_
29-15	4550-4555	IL-1β	_
29-16	4556-4557	,	_
29-17	4558-4561	and	_
29-18	4562-4566	0.24	_
29-19	4567-4572	pg/ml	_
29-20	4573-4576	for	_
29-21	4577-4582	IL-10	_
29-22	4583-4584	,	_
29-23	4585-4588	but	_
29-24	4589-4592	for	_
29-25	4593-4594	a	_
29-26	4595-4601	number	_
29-27	4602-4604	of	_
29-28	4605-4612	samples	_
29-29	4613-4615	we	_
29-30	4616-4620	were	_
29-31	4621-4625	able	_
29-32	4626-4628	to	_
29-33	4629-4637	estimate	_
29-34	4638-4644	values	_
29-35	4645-4648	for	_
29-36	4649-4656	samples	_
29-37	4657-4662	below	_
29-38	4663-4668	these	_
29-39	4669-4675	limits	_
29-40	4676-4677	.	_

30-1	4678-4681	Our	_
30-2	4682-4687	assay	_
30-3	4688-4697	detection	_
30-4	4698-4704	limits	_
30-5	4705-4709	were	_
30-6	4710-4714	0.06	_
30-7	4715-4716	–	_
30-8	4717-4722	3,719	_
30-9	4723-4728	pg/ml	_
30-10	4729-4732	for	_
30-11	4733-4737	IL-6	_
30-12	4738-4739	,	_
30-13	4740-4744	0.04	_
30-14	4745-4746	–	_
30-15	4747-4752	1,612	_
30-16	4753-4758	pg/ml	_
30-17	4759-4762	for	_
30-18	4763-4768	IL-1β	_
30-19	4769-4770	,	_
30-20	4771-4774	and	_
30-21	4775-4779	0.09	_
30-22	4780-4781	–	_
30-23	4782-4787	2,488	_
30-24	4788-4793	pg/ml	_
30-25	4794-4797	for	_
30-26	4798-4803	IL-10	_
30-27	4804-4805	.	_

31-1	4806-4808	In	_
31-2	4809-4814	order	_
31-3	4815-4817	to	_
31-4	4818-4824	assess	_
31-5	4825-4828	the	_
31-6	4829-4840	reliability	_
31-7	4841-4843	of	_
31-8	4844-4847	the	_
31-9	4848-4856	cytokine	_
31-10	4857-4869	measurements	_
31-11	4870-4871	,	_
31-12	4872-4874	we	_
31-13	4875-4885	calculated	_
31-14	4886-4889	the	_
31-15	4890-4896	intra-	_
31-16	4897-4900	and	_
31-17	4901-4912	inter-assay	_
31-18	4913-4925	coefficients	_
31-19	4926-4928	of	_
31-20	4929-4939	variations	_
31-21	4940-4941	(	_
31-22	4942-4945	CVs	_
31-23	4946-4947	)	_
31-24	4948-4950	as	_
31-25	4951-4958	indices	_
31-26	4959-4961	of	_
31-27	4962-4969	within-	_
31-28	4970-4973	and	_
31-29	4974-4987	between-assay	_
31-30	4988-4997	precision	_
31-31	4998-4999	,	_
31-32	5000-5012	respectively	_
31-33	5013-5014	.	_

32-1	5015-5018	The	_
32-2	5019-5026	average	_
32-3	5027-5038	intra-assay	_
32-4	5039-5040	%	_
32-5	5041-5044	CVs	_
32-6	5045-5048	for	_
32-7	5049-5052	the	_
32-8	5053-5061	cytokine	_
32-9	5062-5070	measures	_
32-10	5071-5075	were	_
32-11	5076-5079	8.8	_
32-12	5080-5081	%	_
32-13	5082-5085	for	_
32-14	5086-5090	IL-6	_
32-15	5091-5092	,	_
32-16	5093-5097	11.4	_
32-17	5098-5099	%	_
32-18	5100-5103	for	_
32-19	5104-5109	IL-1β	_
32-20	5110-5111	,	_
32-21	5112-5115	and	_
32-22	5116-5119	9.9	_
32-23	5120-5121	%	_
32-24	5122-5125	for	_
32-25	5126-5131	IL-10	_
32-26	5132-5133	,	_
32-27	5134-5139	which	_
32-28	5140-5143	are	_
32-29	5144-5154	comparable	_
32-30	5155-5157	to	_
32-31	5158-5159	,	_
32-32	5160-5162	or	_
32-33	5163-5168	lower	_
32-34	5169-5173	than	_
32-35	5174-5175	,	_
32-36	5176-5183	similar	_
32-37	5184-5195	multiplexed	_
32-38	5196-5204	cytokine	_
32-39	5205-5213	analysis	_
32-40	5214-5215	.	_

33-1	5216-5219	The	_
33-2	5220-5231	inter-assay	_
33-3	5232-5233	%	_
33-4	5234-5237	CVs	_
33-5	5238-5239	(	_
33-6	5240-5247	indices	_
33-7	5248-5250	of	_
33-8	5251-5265	plate-to-plate	_
33-9	5266-5277	consistency	_
33-10	5278-5279	)	_
33-11	5280-5284	were	_
33-12	5285-5295	calculated	_
33-13	5296-5299	for	_
33-14	5300-5303	low	_
33-15	5304-5307	and	_
33-16	5308-5312	high	_
33-17	5313-5320	control	_
33-18	5321-5328	samples	_
33-19	5329-5333	with	_
33-20	5334-5339	known	_
33-21	5340-5348	cytokine	_
33-22	5349-5363	concentrations	_
33-23	5364-5365	.	_

34-1	5366-5369	The	_
34-2	5370-5377	average	_
34-3	5378-5380	of	_
34-4	5381-5384	the	_
34-5	5385-5388	low	_
34-6	5389-5392	and	_
34-7	5393-5397	high	_
34-8	5398-5399	%	_
34-9	5400-5403	CVs	_
34-10	5404-5408	were	_
34-11	5409-5413	14.5	_
34-12	5414-5415	%	_
34-13	5416-5419	for	_
34-14	5420-5424	IL-6	_
34-15	5425-5426	,	_
34-16	5427-5431	27.0	_
34-17	5432-5433	%	_
34-18	5434-5437	for	_
34-19	5438-5443	IL-1β	_
34-20	5444-5445	,	_
34-21	5446-5449	and	_
34-22	5450-5453	8.2	_
34-23	5454-5455	%	_
34-24	5456-5459	for	_
34-25	5460-5465	IL-10	_
34-26	5466-5467	.	_

35-1	5468-5472	This	_
35-2	5473-5482	variation	_
35-3	5483-5485	is	_
35-4	5486-5496	comparable	_
35-5	5497-5499	to	_
35-6	5500-5510	previously	_
35-7	5511-5519	reported	_
35-8	5520-5531	inter-assay	_
35-9	5532-5535	CVs	_
35-10	5536-5541	using	_
35-11	5542-5546	this	_
35-12	5547-5553	method	_
35-13	5554-5555	.	_

36-1	5556-5559	2.4	_
36-2	5560-5561	.	_

37-1	5562-5565	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
37-2	5566-5573	imaging	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
37-3	5574-5585	acquisition	_
37-4	5586-5593	Imaging	_
37-5	5594-5597	was	_
37-6	5598-5607	performed	_
37-7	5608-5610	on	_
37-8	5611-5612	a	_
37-9	5613-5614	3	_
37-10	5615-5620	Tesla	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
37-11	5621-5628	Siemens	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
37-12	5629-5632	TIM	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
37-13	5633-5637	Trio	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
37-14	5638-5641	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
37-15	5642-5649	scanner	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
37-16	5650-5651	.	_

38-1	5652-5653	A	_
38-2	5654-5663	localizer	_
38-3	5664-5668	scan	_
38-4	5669-5672	was	_
38-5	5673-5681	acquired	_
38-6	5682-5684	in	_
38-7	5685-5690	order	_
38-8	5691-5693	to	_
38-9	5694-5699	guide	_
38-10	5700-5705	slice	_
38-11	5706-5715	alignment	_
38-12	5716-5722	during	_
38-13	5723-5733	anatomical	_
38-14	5734-5737	and	_
38-15	5738-5748	functional	_
38-16	5749-5754	scans	_
38-17	5755-5756	.	_

39-1	5757-5758	A	_
39-2	5759-5761	T2	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
39-3	5762-5763	*	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
39-4	5764-5765	-	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
39-5	5766-5774	weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
39-6	5775-5786	echo-planar	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
39-7	5787-5792	image	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
39-8	5793-5794	(	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
39-9	5795-5798	EPI	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
39-10	5799-5800	)	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
39-11	5801-5804	was	_
39-12	5805-5813	acquired	_
39-13	5814-5815	(	_
39-14	5816-5818	24	_
39-15	5819-5825	slices	_
39-16	5826-5827	,	_
39-17	5828-5829	4	_
39-18	5830-5832	mm	_
39-19	5833-5838	thick	_
39-20	5839-5840	,	_
39-21	5841-5844	gap	_
39-22	5845-5850	width	_
39-23	5851-5852	=	_
39-24	5853-5854	1	_
39-25	5855-5857	mm	_
39-26	5858-5859	,	_
39-27	5860-5867	TR/TE/α	_
39-28	5868-5869	=	_
39-29	5870-5875	2,000	_
39-30	5876-5881	ms/40	_
39-31	5882-5888	ms/80°	_
39-32	5889-5890	,	_
39-33	5891-5897	matrix	_
39-34	5898-5899	=	_
39-35	5900-5903	128	_
39-36	5904-5905	×	_
39-37	5906-5909	128	_
39-38	5910-5911	,	_
39-39	5912-5915	FOV	_
39-40	5916-5917	=	_
39-41	5918-5921	240	_
39-42	5922-5925	mm2	_
39-43	5926-5927	,	_
39-44	5928-5931	170	_
39-45	5932-5939	volumes	_
39-46	5940-5941	,	_
39-47	5942-5950	in-plane	_
39-48	5951-5956	pixel	_
39-49	5957-5961	size	_
39-50	5962-5964	of	_
39-51	5965-5970	1.875	_
39-52	5971-5974	mm2	_
39-53	5975-5976	)	_
39-54	5977-5982	while	_
39-55	5983-5991	subjects	_
39-56	5992-5998	stared	_
39-57	5999-6001	at	_
39-58	6002-6003	a	_
39-59	6004-6009	white	_
39-60	6010-6015	cross	_
39-61	6016-6018	on	_
39-62	6019-6020	a	_
39-63	6021-6026	black	_
39-64	6027-6033	screen	_
39-65	6034-6035	.	_

40-1	6036-6039	One	_
40-2	6040-6055	high-resolution	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk
40-3	6056-6067	T1-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
40-4	6068-6078	anatomical	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
40-5	6079-6091	magnetically	_
40-6	6092-6100	prepared	http://maven.renci.org/NeuroBridge/neurobridge#AcutePain
40-7	6101-6106	rapid	_
40-8	6107-6118	acquisition	http://maven.renci.org/NeuroBridge/neurobridge#Education
40-9	6119-6127	gradient	http://maven.renci.org/NeuroBridge/neurobridge#Education
40-10	6128-6132	echo	http://maven.renci.org/NeuroBridge/neurobridge#Education
40-11	6133-6134	(	_
40-12	6135-6141	MPRAGE	_
40-13	6142-6143	;	_
40-14	6144-6147	144	_
40-15	6148-6154	slices	_
40-16	6155-6156	1	_
40-17	6157-6159	mm	_
40-18	6160-6165	thick	_
40-19	6166-6167	,	_
40-20	6168-6178	TR/TE/TI/α	_
40-21	6179-6180	=	_
40-22	6181-6186	2,300	_
40-23	6187-6194	ms/4.38	_
40-24	6195-6203	ms/1,200	_
40-25	6204-6210	ms/12°	_
40-26	6211-6212	,	_
40-27	6213-6216	FOV	_
40-28	6217-6218	=	_
40-29	6219-6222	208	_
40-30	6223-6224	×	_
40-31	6225-6228	256	_
40-32	6229-6232	mm2	_
40-33	6233-6234	)	_
40-34	6235-6238	was	_
40-35	6239-6247	acquired	_
40-36	6248-6251	for	_
40-37	6252-6267	co-registration	_
40-38	6268-6272	with	_
40-39	6273-6283	functional	_
40-40	6284-6290	images	_
40-41	6291-6294	and	_
40-42	6295-6306	statistical	_
40-43	6307-6314	overlay	_
40-44	6315-6316	.	_

41-1	6317-6320	2.5	_
41-2	6321-6322	.	_

42-1	6323-6336	Resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
42-2	6337-6341	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
42-3	6342-6350	analysis	_
42-4	6351-6356	Three	_
42-5	6357-6369	participants	_
42-6	6370-6372	in	_
42-7	6373-6376	the	_
42-8	6377-6379	MA	_
42-9	6380-6385	group	_
42-10	6386-6390	were	_
42-11	6391-6399	excluded	_
42-12	6400-6403	for	_
42-13	6404-6414	incomplete	_
42-14	6415-6419	scan	_
42-15	6420-6431	acquisition	_
42-16	6432-6435	due	_
42-17	6436-6438	to	_
42-18	6439-6448	technical	_
42-19	6449-6461	difficulties	_
42-20	6462-6463	.	_

43-1	6464-6466	On	_
43-2	6467-6470	the	_
43-3	6471-6480	remaining	_
43-4	6481-6488	subject	_
43-5	6489-6493	data	_
43-6	6494-6495	,	_
43-7	6496-6501	image	_
43-8	6502-6510	analysis	_
43-9	6511-6514	was	_
43-10	6515-6524	performed	_
43-11	6525-6530	using	_
43-12	6531-6534	FSL	_
43-13	6535-6542	5.0.2.1	_
43-14	6543-6544	(	_
43-15	6545-6567	www.fmrib.ox.ac.uk/fsl	_
43-16	6568-6569	)	_
43-17	6570-6571	.	_

44-1	6572-6578	Images	_
44-2	6579-6583	were	_
44-3	6584-6593	realigned	_
44-4	6594-6596	to	_
44-5	6597-6607	compensate	_
44-6	6608-6611	for	_
44-7	6612-6618	motion	_
44-8	6619-6620	,	_
44-9	6621-6624	and	_
44-10	6625-6634	high-pass	_
44-11	6635-6643	temporal	_
44-12	6644-6653	filtering	_
44-13	6654-6655	(	_
44-14	6656-6659	100	_
44-15	6660-6661	s	_
44-16	6662-6663	)	_
44-17	6664-6667	was	_
44-18	6668-6675	applied	_
44-19	6676-6677	.	_

45-1	6678-6682	Data	_
45-2	6683-6687	were	_
45-3	6688-6702	skull-stripped	_
45-4	6703-6706	and	_
45-5	6707-6716	spatially	_
45-6	6717-6725	smoothed	_
45-7	6726-6727	(	_
45-8	6728-6732	5-mm	_
45-9	6733-6737	FWHM	_
45-10	6738-6746	Gaussian	_
45-11	6747-6753	kernel	_
45-12	6754-6755	)	_
45-13	6756-6757	.	_

46-1	6758-6764	Images	_
46-2	6765-6769	were	_
46-3	6770-6777	further	_
46-4	6778-6791	pre-processed	_
46-5	6792-6794	to	_
46-6	6795-6802	include	_
46-7	6803-6813	additional	_
46-8	6814-6822	nuisance	_
46-9	6823-6833	regressors	_
46-10	6834-6835	:	_
46-11	6836-6843	average	_
46-12	6844-6850	signal	_
46-13	6851-6853	of	_
46-14	6854-6867	cerebrospinal	_
46-15	6868-6873	fluid	_
46-16	6874-6875	,	_
46-17	6876-6883	average	_
46-18	6884-6890	signal	_
46-19	6891-6895	from	_
46-20	6896-6908	white-matter	_
46-21	6909-6910	,	_
46-22	6911-6914	and	_
46-23	6915-6918	two	_
46-24	6919-6926	metrics	_
46-25	6927-6929	of	_
46-26	6930-6944	motion-related	_
46-27	6945-6953	artifact	_
46-28	6954-6955	,	_
46-29	6956-6968	specifically	_
46-30	6969-6975	motion	_
46-31	6976-6985	scrubbing	_
46-32	6986-6990	with	_
46-33	6991-7001	frame-wise	_
46-34	7002-7014	displacement	_
46-35	7015-7018	and	_
46-36	7019-7020	a	_
46-37	7021-7032	combination	_
46-38	7033-7035	of	_
46-39	7036-7039	the	_
46-40	7040-7048	temporal	_
46-41	7049-7059	derivative	_
46-42	7060-7062	of	_
46-43	7063-7066	the	_
46-44	7067-7071	time	_
46-45	7072-7078	series	_
46-46	7079-7082	and	_
46-47	7083-7100	root-mean-squared	_
46-48	7101-7109	variance	_
46-49	7110-7114	over	_
46-50	7115-7118	all	_
46-51	7119-7125	voxels	_
46-52	7126-7127	.	_

47-1	7128-7134	Global	_
47-2	7135-7141	signal	_
47-3	7142-7152	regression	_
47-4	7153-7156	was	_
47-5	7157-7160	not	_
47-6	7161-7168	applied	_
47-7	7169-7170	.	_

48-1	7171-7174	The	_
48-2	7175-7178	EPI	_
48-3	7179-7185	images	_
48-4	7186-7190	were	_
48-5	7191-7201	registered	_
48-6	7202-7204	to	_
48-7	7205-7208	the	_
48-8	7209-7224	high-resolution	_
48-9	7225-7231	MPRAGE	_
48-10	7232-7237	image	_
48-11	7238-7241	and	_
48-12	7242-7246	then	_
48-13	7247-7251	into	_
48-14	7252-7260	standard	_
48-15	7261-7269	Montreal	_
48-16	7270-7282	Neurological	_
48-17	7283-7292	Institute	_
48-18	7293-7298	space	_
48-19	7299-7300	,	_
48-20	7301-7306	using	_
48-21	7307-7308	a	_
48-22	7309-7321	12-parameter	_
48-23	7322-7328	affine	_
48-24	7329-7343	transformation	_
48-25	7344-7345	.	_

49-1	7346-7348	An	_
49-2	7349-7369	anatomically-defined	_
49-3	7370-7376	region	_
49-4	7377-7379	of	_
49-5	7380-7388	interest	_
49-6	7389-7393	from	_
49-7	7394-7397	the	_
49-8	7398-7412	Harvard-Oxford	_
49-9	7413-7424	Subcortical	_
49-10	7425-7430	atlas	_
49-11	7431-7433	of	_
49-12	7434-7437	the	_
49-13	7438-7445	ventral	_
49-14	7446-7454	striatum	_
49-15	7455-7458	and	_
49-16	7459-7460	a	_
49-17	7461-7470	spherical	_
49-18	7471-7474	ROI	_
49-19	7475-7477	of	_
49-20	7478-7481	the	_
49-21	7482-7487	DLPFC	_
49-22	7488-7489	(	_
49-23	7490-7498	Montreal	_
49-24	7499-7511	Neurological	_
49-25	7512-7521	Institute	_
49-26	7522-7533	coordinates	_
49-27	7534-7535	:	_
49-28	7536-7537	x	_
49-29	7538-7539	=	_
49-30	7540-7542	30	_
49-31	7543-7544	,	_
49-32	7545-7546	y	_
49-33	7547-7548	=	_
49-34	7549-7551	36	_
49-35	7552-7553	,	_
49-36	7554-7555	z	_
49-37	7556-7557	=	_
49-38	7558-7560	20	_
49-39	7561-7562	)	_
49-40	7563-7567	were	_
49-41	7568-7572	used	_
49-42	7573-7575	as	_
49-43	7576-7581	seeds	_
49-44	7582-7584	in	_
49-45	7585-7588	two	_
49-46	7589-7597	separate	_
49-47	7598-7606	analyses	_
49-48	7607-7608	.	_

50-1	7609-7612	The	_
50-2	7613-7618	seeds	_
50-3	7619-7623	were	_
50-4	7624-7635	transformed	_
50-5	7636-7640	into	_
50-6	7641-7645	each	_
50-7	7646-7653	subject	_
50-8	7654-7655	’	_
50-9	7656-7657	s	_
50-10	7658-7664	native	_
50-11	7665-7670	space	_
50-12	7671-7673	by	_
50-13	7674-7682	applying	_
50-14	7683-7686	the	_
50-15	7687-7695	inverted	_
50-16	7696-7710	transformation	_
50-17	7711-7717	matrix	_
50-18	7718-7720	of	_
50-19	7721-7724	EPI	_
50-20	7725-7727	to	_
50-21	7728-7734	MPRAGE	_
50-22	7735-7737	to	_
50-23	7738-7746	standard	_
50-24	7747-7752	space	_
50-25	7753-7754	.	_

51-1	7755-7757	In	_
51-2	7758-7766	separate	_
51-3	7767-7778	whole-brain	_
51-4	7779-7780	,	_
51-5	7781-7791	voxel-wise	_
51-6	7792-7805	resting-state	_
51-7	7806-7814	analyses	_
51-8	7815-7816	,	_
51-9	7817-7820	the	_
51-10	7821-7825	mean	_
51-11	7826-7830	time	_
51-12	7831-7837	series	_
51-13	7838-7844	across	_
51-14	7845-7848	all	_
51-15	7849-7855	voxels	_
51-16	7856-7862	within	_
51-17	7863-7866	the	_
51-18	7867-7875	striatum	_
51-19	7876-7880	seed	_
51-20	7881-7884	and	_
51-21	7885-7891	within	_
51-22	7892-7895	the	_
51-23	7896-7901	DLPFC	_
51-24	7902-7906	seed	_
51-25	7907-7911	from	_
51-26	7912-7925	pre-processed	_
51-27	7926-7932	images	_
51-28	7933-7937	were	_
51-29	7938-7945	entered	_
51-30	7946-7948	as	_
51-31	7949-7959	covariates	_
51-32	7960-7961	.	_

52-1	7962-7965	For	_
52-2	7966-7968	IL	_
52-3	7969-7976	markers	_
52-4	7977-7981	that	_
52-5	7982-7988	showed	_
52-6	7989-8000	significant	_
52-7	8001-8006	group	_
52-8	8007-8018	differences	_
52-9	8019-8020	,	_
52-10	8021-8034	between-group	_
52-11	8035-8048	mixed-effects	_
52-12	8049-8057	analyses	_
52-13	8058-8062	were	_
52-14	8063-8072	conducted	_
52-15	8073-8077	with	_
52-16	8078-8080	IL	_
52-17	8081-8095	concentrations	_
52-18	8096-8098	as	_
52-19	8099-8109	regressors	_
52-20	8110-8112	to	_
52-21	8113-8117	test	_
52-22	8118-8123	group	_
52-23	8124-8136	interactions	_
52-24	8137-8139	in	_
52-25	8140-8151	whole-brain	_
52-26	8152-8162	voxel-wise	_
52-27	8163-8173	regression	_
52-28	8174-8176	of	_
52-29	8177-8185	striatum	_
52-30	8186-8189	and	_
52-31	8190-8195	DLPFC	_
52-32	8196-8200	RSFC	_
52-33	8201-8202	(	_
52-34	8203-8206	see	_
52-35	8207-8214	Section	_
52-36	8215-8219	2.6.	_
52-37	8220-8223	for	_
52-38	8224-8231	further	_
52-39	8232-8243	description	_
52-40	8244-8246	of	_
52-41	8247-8258	statistical	_
52-42	8259-8267	analyses	_
52-43	8268-8269	)	_
52-44	8270-8271	.	_

53-1	8272-8275	All	_
53-2	8276-8287	whole-brain	_
53-3	8288-8292	fMRI	_
53-4	8293-8303	statistics	_
53-5	8304-8308	were	_
53-6	8309-8318	corrected	_
53-7	8319-8322	for	_
53-8	8323-8331	multiple	_
53-9	8332-8343	comparisons	_
53-10	8344-8346	by	_
53-11	8347-8352	using	_
53-12	8353-8371	cluster-correction	_
53-13	8372-8376	with	_
53-14	8377-8382	voxel	_
53-15	8383-8389	height	_
53-16	8390-8399	threshold	_
53-17	8400-8402	of	_
53-18	8403-8404	Z	_
53-19	8405-8406	>	_
53-20	8407-8410	2.3	_
53-21	8411-8414	and	_
53-22	8415-8422	cluster	_
53-23	8423-8435	significance	_
53-24	8436-8438	of	_
53-25	8439-8440	P	_
53-26	8441-8442	<	_
53-27	8443-8447	0.05	_
53-28	8448-8449	.	_

54-1	8450-8453	2.6	_
54-2	8454-8455	.	_

55-1	8456-8467	Statistical	_
55-2	8468-8476	analysis	_
55-3	8477-8484	Student	_
55-4	8485-8486	’	_
55-5	8487-8488	s	_
55-6	8489-8496	t-tests	_
55-7	8497-8500	and	_
55-8	8501-8512	chi-squared	_
55-9	8513-8514	(	_
55-10	8515-8517	χ2	_
55-11	8518-8519	)	_
55-12	8520-8525	tests	_
55-13	8526-8530	were	_
55-14	8531-8535	used	_
55-15	8536-8538	to	_
55-16	8539-8546	compare	_
55-17	8547-8553	groups	_
55-18	8554-8556	in	_
55-19	8557-8568	demographic	_
55-20	8569-8572	and	_
55-21	8573-8582	substance	_
55-22	8583-8586	use	_
55-23	8587-8596	variables	_
55-24	8597-8598	.	_

56-1	8599-8600	A	_
56-2	8601-8607	linear	_
56-3	8608-8618	regression	_
56-4	8619-8622	was	_
56-5	8623-8627	used	_
56-6	8628-8630	to	_
56-7	8631-8635	test	_
56-8	8636-8639	for	_
56-9	8640-8643	the	_
56-10	8644-8648	main	_
56-11	8649-8656	effects	_
56-12	8657-8659	of	_
56-13	8660-8665	group	_
56-14	8666-8667	,	_
56-15	8668-8671	age	_
56-16	8672-8673	,	_
56-17	8674-8677	and	_
56-18	8678-8681	sex	_
56-19	8682-8684	on	_
56-20	8685-8696	differences	_
56-21	8697-8699	in	_
56-22	8700-8704	IL-6	_
56-23	8705-8706	,	_
56-24	8707-8712	IL-1β	_
56-25	8713-8716	and	_
56-26	8717-8722	IL-10	_
56-27	8723-8737	concentrations	_
56-28	8738-8739	.	_

57-1	8740-8742	In	_
57-2	8743-8751	addition	_
57-3	8752-8753	,	_
57-4	8754-8759	given	_
57-5	8760-8763	the	_
57-6	8764-8774	non-normal	_
57-7	8775-8787	distribution	_
57-8	8788-8790	of	_
57-9	8791-8796	IL-10	_
57-10	8797-8811	concentrations	_
57-11	8812-8813	,	_
57-12	8814-8815	a	_
57-13	8816-8829	nonparametric	_
57-14	8830-8842	Mann-Whitney	_
57-15	8843-8847	test	_
57-16	8848-8851	was	_
57-17	8852-8861	conducted	_
57-18	8862-8863	.	_

58-1	8864-8875	Statistical	_
58-2	8876-8884	analysis	_
58-3	8885-8888	was	_
58-4	8889-8898	conducted	_
58-5	8899-8904	using	_
58-6	8905-8909	SPSS	_
58-7	8910-8912	24	_
58-8	8913-8914	(	_
58-9	8915-8921	Armonk	_
58-10	8922-8923	,	_
58-11	8924-8926	NY	_
58-12	8927-8928	:	_
58-13	8929-8932	IBM	_
58-14	8933-8937	Corp	_
58-15	8938-8939	)	_
58-16	8940-8941	.	_

